GlassScriptPhysician profile
Kenneth M Chan
NPI 1861422370
$1,740.25
in general payments reported to CMS, 2019-2025
20 companies · $785 in 2025
The $785 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.77 · 2021: $30.67 · 2023: $26.58 · 2024: $886 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $356.46 | 2024-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $227.64 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $208.40 | 2025 | Voquezna |
| Gilead Sciences, INC. | $194.29 | 2025 | |
| Novo Nordisk INC | $115.89 | 2020-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $88.48 | 2024-2025 | |
| Lilly USA, LLC | $66.59 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $65.98 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $65.80 | 2024-2025 | Zoryve |
| Amgen INC. | $62.79 | 2024-2025 | Evenity, Prolia, Repatha |
| Lexicon Pharmaceuticals, INC. | $58.82 | 2024 | |
| Glaxosmithkline, LLC. | $52.38 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.49 | 2025 | Jardiance |
| Dexcom, INC. | $23.37 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $23.28 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.35 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $19.50 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.13 | 2024 | Xifaxan |
| Redhill Biopharma INC. | $17.61 | 2025 | Talicia |
| Ironwood Pharmaceuticals, INC | $17.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.